Anonymous wrote:
Anonymous wrote:
Anonymous wrote:
Anonymous wrote:My husband took it, it is a long acting amphetamine. Used for treatment of ADD. I am sure someone would take it for weight loss, or energy. It is dangerous, my husband had an undiagnosed heart valve defect, and this drug made it a lot worse. He is off of it for now, but he was pretty addicted to it.
In what way was he addicted to it? It doesn't provide the rush that other stimulants provide and it generally takes a while for the drug to leave the body so you don't crash when you miss a dose.
All of the info I've read online says that it is highly addictive and does indeed cause a high. Not all forms of the med is extended release, as well.
I don't think you're reading about Vyvanse because it only comes in extended release. There are several strengths but they are ALL extended release. Perhaps you're reading about amphetamines in general? There are many types of amphetamines and people react to and metabolize them differently, that's why it's so important to work with a doctor skilled in using psychostimulants. Vyvanse is not physically addictive and, as the PP noted, doesn't provide a high even when crushed and snorted. It's nothing at all like caffeine, cigarettes, opiates or crystal meth.
Drug Abuse and Dependence
Controlled Substance
Vyvanse is classified as a Schedule II controlled substance.
Abuse and Dependence
Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to levels many times higher than recommended. Abrupt cessation following prolonged high-dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with amphetamines may include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.
Human Studies
In a human abuse liability study, when equivalent oral doses of 100 mg lisdexamfetamine dimesylate and 40 mg immediate-release d-amphetamine sulfate were administered to individuals with a history of drug abuse, lisdexamfetamine dimesylate 100 mg produced subjective responses on a scale of "Drug Liking Effects" (primary endpoint) that were significantly less than d-amphetamine immediate-release 40 mg. However, oral administration of 150 mg lisdexamfetamine dimesylate produced increases in positive subjective responses on this scale that were statistically indistinguishable from the positive subjective responses produced by 40 mg of oral immediate-release d-amphetamine and 200 mg of diethylpropion (C-IV).1
Intravenous administration of 50 mg lisdexamfetamine dimesylate to individuals with a history of drug abuse produced positive subjective responses on scales measuring "Drug Liking", "Euphoria", "Amphetamine Effects", and "Benzedrine Effects" that were greater than placebo but less than those produced by an equivalent dose (20 mg) of intravenous d-amphetamine.
Animal Studies
In animal studies, lisdexamfetamine dimesylate produced behavioral effects qualitatively similar to those of the CNS stimulant d-amphetamine. In monkeys trained to self-administer cocaine, intravenous lisdexamfetamine dimesylate maintained self-administration at a rate that was statistically less than that for cocaine, but greater than that of placebo.